Melanoma and Resectable Solid Tumors
Io Biotech ApS focuses on melanoma and other selected resectable tumors, with clinical activity centered on treatment around surgery and the assessment of major pathological response in tumor tissue.
- Neoadjuvant immunotherapy
- Post-surgical treatment
- Advanced melanoma
The sponsor’s work in this area reflects a strong therapeutic interest in integrating immune-based treatment with surgical management for patients with operable disease.
Metastatic Non-Small Cell Lung Cancer
Clinical research includes metastatic non-small cell lung cancer, with attention to first-line treatment and outcomes in patients with PD-L1–positive disease.
- Frontline metastatic NSCLC
- PD-L1–selected populations
- Progression-free survival
This area shows a clear therapeutic focus on advanced lung cancer and the use of immunotherapy combinations in the metastatic setting.
Head and Neck Squamous Cell Carcinoma
The sponsor is active in squamous cell carcinoma of the head and neck, including metastatic disease and locally advanced tumors studied in relation to PD-L1 expression.
- Metastatic SCCHN
- Immune checkpoint combination therapy
- Biomarker-selected treatment
Research in this field is directed toward improving treatment options for patients with head and neck cancer who have limited therapeutic choices in the metastatic setting.
Urothelial Bladder Cancer
Io Biotech ApS also supports studies in metastatic urothelial bladder cancer, with a focus on patients receiving initial systemic therapy and those identified by PD-L1 criteria.
- Metastatic urothelial carcinoma
- First-line immunotherapy
- Biomarker-driven selection
This therapeutic area highlights the sponsor’s involvement in bladder cancer research where immune-based treatment strategies are being explored for advanced disease.
